The drug for Alzheimer’s disease given the green light by safety regulators in the United Kingdom on Thursday will not be funded by the NHS. That means it won't be available for purchase on NHS and patients will need to buy it privately.

New Alzheimer’s drug too costly, benefits too small, UK's health body says. 'Just not enough...'

alzheimers-medicine

Alzheimer’s Medicine, News on Alzheimer’s Medicine, stories on Alzheimer’s Medicine, articles on Alzheimer’s Medicine, Alzheimer’s Medicine stories at Wion, Alzheimer’s Medicine news, Alzheimer’s Medicine latest news

alzheimers medicine

New Alzheimer’s drug too costly, benefits too small, UK's health body says. 'Just not enough...'